Perigon Wealth Management LLC Invests $574,000 in Edwards Lifesciences Corporation $EW

Perigon Wealth Management LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, HoldingsChannel reports. The fund bought 6,349 shares of the medical research company’s stock, valued at approximately $574,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $25,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,570 shares of company stock worth $2,219,390 in the last three months. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Stock Up 1.5%

Edwards Lifesciences stock opened at $92.36 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a 50-day simple moving average of $89.03 and a 200-day simple moving average of $84.57. The firm has a market capitalization of $53.18 billion, a P/E ratio of 53.08, a P/E/G ratio of 2.29 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the business posted $0.67 EPS. Edwards Lifesciences’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. UBS Group assumed coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target for the company. Barclays reaffirmed an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Truist Financial upped their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.